Celecoxib does not affect osteointegration of cementless total hip stems.
Celecoxib's effect on prosthetic osteointegration in patients undergoing total hip arthroplasty was studied. In a prospective, placebo-controlled, double-blind study of 49 patients, 24 were randomized to celecoxib (200 mg/d) and 25 to placebo over 6 weeks. Bone markers, N-teleopeptide, and bone-specific alkaline phosphatase were obtained postoperatively, and at 6 and 12 weeks. No radiographic prosthetic subsidence occurred. There were no significant differences from baseline in periprosthetic bone mineral density between the celecoxib and placebo groups at 3 and 6 months. There were no significant differences in baseline BSAlkP values between the 2 groups. At 6 and 12 weeks, average BSAlkP values increased. Urinary NTx concentrations followed a skewed distribution. Normalized NTx concentrations were statistically significantly greater in the celecoxib group than the placebo group at 6 weeks but not at 12 weeks.
Lionberger
David R
DR
Orthopedic Surgery Department, Baylor College of Medicine, Houston, Texas 77030, USA.
Noble
Philip C
PC
D000368:Aged; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000494:pharmacology*; D015519:Bone Density; D000068579:Celecoxib; D004311:Double-Blind Method; D005260:Female; D006622:Hip Prosthesis; D006801:Humans; D008297:Male; D008875:Middle Aged; D016348:Osseointegration / Q000187:drug effects*; D011446:Prospective Studies; D011474:Prosthesis Design; D011720:Pyrazoles / Q000494:pharmacology*; D013449:Sulfonamides / Q000494:pharmacology*
D000894:Anti-Inflammatory Agents, Non-Steroidal; D011720:Pyrazoles; D013449:Sulfonamides; D000068579:Celecoxib